Reni Benjamin is ranked #2560 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Reni Benjamin (Citizens JMP) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Reni Benjamin's stock ratings?

About 29% of Reni's ratings were profitable over a one-year hold, with an average return of -0.5% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Reni Benjamin

Reni Benjamin

Citizens JMP

Wall Street Analyst

★☆☆☆☆

#2560

on 13Foresight · ranked by our own returns

29%

Success Rate

-0.5%

Average Return

14 of 49 calls profitable · -11.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 29% of Reni Benjamin's ratings turned a profit when each position was held for 1 year — averaging -0.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

29 Buy 13 Hold 0 Sell

Reni's Stock Coverage 58 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
STRO Sutro Biopharma	Apr 23, 2026	BUY	Strong Buy +31.6% avg upside 20 analysts	$41.00 38.32% Upside	-17.3%
WHWK Whitehawk Therapeutics	Apr 16, 2026	BUY	Buy +201.4% avg upside 12 analysts	$8.00 80.94% Upside	-0.2%
ALLO Allogene Therapeutics	Apr 14, 2026	BUY	Strong Buy +662.1% avg upside 28 analysts	$8.00 299.96% Upside	-16.7%
BCYC Bicycle Therapeutics	Mar 18, 2026	BUY	Strong Buy +505.6% avg upside 20 analysts	$8.00 99.93% Upside	-7.2%
IMMP Immutep	Mar 13, 2026	HOLD	Strong Buy +1343.0% avg upside 7 analysts	—	-8.3%
PRLD Prelude Therapeutics	Mar 11, 2026	BUY	Buy +151.3% avg upside 7 analysts	$6.00 38.86% Upside	+17.6%
LYEL Lyell Immunopharma	Mar 09, 2026	BUY	Buy +96.2% avg upside 10 analysts	$34.00 166.90% Upside	-53.1%
IMMX Immix Biopharma	Mar 09, 2026	BUY	Strong Buy +105.0% avg upside 8 analysts	$23.00 163.78% Upside	-13.3%
IOVA Iovance Biotherapeutics	Feb 25, 2026	BUY	Strong Buy +225.8% avg upside 24 analysts	$5.00 27.94% Upside	-9.9%
BCAX Bicara Therapeutics Inc.	Jan 29, 2026	BUY	Strong Buy +34.1% avg upside 14 analysts	$31.00 33.44% Upside	+35.5%
HOWL Werewolf Therapeutics	Dec 19, 2025	HOLD	Strong Buy +1864.2% avg upside 8 analysts	—	-49.9%
CMPX Compass Therapeutics	Dec 03, 2025	BUY	Strong Buy +373.4% avg upside 19 analysts	$10.00 395.04% Upside	+0.9%
ZYME Zymeworks	Dec 03, 2025	BUY	Strong Buy +40.3% avg upside 25 analysts	$32.00 38.31% Upside	-14.2%
ONC BeOne Medicines	Nov 07, 2025	BUY	Strong Buy +28.4% avg upside 28 analysts	$396.00 46.68% Upside	-17.9%
SANA Sana Biotechnology	Oct 30, 2025	BUY	Strong Buy +214.8% avg upside 14 analysts	$8.00 154.01% Upside	-42.2%
ACET Adicet Bio	Oct 08, 2025	HOLD	Strong Buy +212.8% avg upside 14 analysts	—	-45.1%
KURA Kura Oncology	Sep 30, 2025	BUY	Strong Buy +161.3% avg upside 26 analysts	$24.00 141.78% Upside	+8.1%
INCY Incyte	Sep 18, 2025	HOLD	Buy +1.0% avg upside 47 analysts	—	+15.1%
BCAB BioAtla	Sep 09, 2025	HOLD	Strong Buy +2518.3% avg upside 13 analysts	—	-88.0%
SMMT Summit Therapeutics	Sep 08, 2025	BUY	Strong Buy +112.6% avg upside 27 analysts	$40.00 190.84% Upside	-28.7%
TIL Instil Bio	Aug 15, 2025	HOLD	Buy +343.4% avg upside 8 analysts	—	-72.6%
INBX Inhibrx Biosciences Inc	May 15, 2025	HOLD	Strong Buy +198.3% avg upside 5 analysts	—	+803.8%
CUE Cue Biopharma	Apr 21, 2025	BUY	Strong Buy -66.9% avg upside 9 analysts	$2.00 92.98% Downside	-14.2%
NXTC NextCure	Apr 06, 2023	HOLD	Buy +776.9% avg upside 10 analysts	—	+45.3%
EFTR eFFECTOR Therapeutics	Apr 06, 2023	HOLD	Strong Buy +66249899.9% avg upside 5 analysts	—	-84.0%
CGEN Compugen	Apr 06, 2023	HOLD	Strong Buy +170.1% avg upside 8 analysts	—	+266.7%
VSTM Verastem	May 10, 2019	HOLD	Strong Buy +260.2% avg upside 23 analysts	—	+45.6%
ADAPY Adaptimmune Therapeutics	May 07, 2019	BUY	Buy +5712.5% avg upside 10 analysts	$6.00 14900.06% Upside	·
MGNX MacroGenics	May 02, 2019	HOLD	Buy +326.2% avg upside 25 analysts	—	-61.5%
BMRN BioMarin Pharmaceutical	Apr 09, 2019	BUY	Strong Buy +72.8% avg upside 52 analysts	$110.00 101.17% Upside	-12.9%
LCTX Lineage Therap	Mar 18, 2019	BUY	Strong Buy +342.7% avg upside 16 analysts	$5.00 313.32% Upside	·
URGN Urogen Pharma	Mar 01, 2019	BUY	Strong Buy +13.0% avg upside 16 analysts	$57.00 69.80% Upside	-31.8%
RGNX RegenXBio	Feb 05, 2019	BUY	Strong Buy +381.4% avg upside 22 analysts	$94.00 1105.03% Upside	+4.5%
AKBA Akebia Therapeutics	Dec 13, 2018	BUY	Strong Buy +822.0% avg upside 16 analysts	$21.00 1862.71% Upside	-26.5%
TCRT Alaunos Therapeutics	Nov 15, 2018	BUY	Buy +604.3% avg upside 13 analysts	$5.00 132.63% Upside	+44.8%
VYGR Voyager Therapeutics	Nov 14, 2018	BUY	Strong Buy +284.2% avg upside 23 analysts	—	+16.3%
ADMA ADMA Biologics	Oct 12, 2018	BUY	Strong Buy +57.2% avg upside 15 analysts	$10.00 20.29% Upside	-24.5%
CYPH Cypherpunk Technologies	Aug 28, 2018	BUY	Buy +1087.0% avg upside 9 analysts	$12.87 1641.05% Upside	·
TGTX TG Therapeutics	Aug 14, 2018	BUY	Strong Buy -34.4% avg upside 19 analysts	$22.00 58.64% Downside	·
VIVS VivoSim Labs	Aug 10, 2018	HOLD	Buy +161.4% avg upside 5 analysts	—	-76.1%
FATE Fate Therapeutics	Aug 07, 2018	HOLD	Buy +475.7% avg upside 31 analysts	—	+63.8%
IBRX ImmunityBio	Aug 07, 2018	HOLD	Strong Buy +52.6% avg upside 12 analysts	—	-55.8%
SLS SELLAS Life Sciences Group	Dec 18, 2017	HOLD	Strong Buy +768.2% avg upside 15 analysts	—	-82.6%
OTLC Oncotelic Therapeutics	Jun 04, 2015	BUY	Strong Buy +7468.0% avg upside 5 analysts	$6.00 12283.96% Upside	·
SCPX Scorpius Holdings	May 26, 2015	BUY	Strong Buy +1664672.8% avg upside 11 analysts	$13.00 1181718.26% Upside	·
IMNN Imunon	May 21, 2015	BUY	Strong Buy +705.9% avg upside 11 analysts	$8.00 339.57% Upside	-49.3%
THMO ThermoGenesis Holdings	May 15, 2015	HOLD	Buy +7499899.9% avg upside 4 analysts	—	·
CANF Can-Fite BioPharma	Mar 31, 2015	BUY	Strong Buy +57.3% avg upside 8 analysts	$3.00 0.76% Upside	+25.1%
PHIO Phio Pharmaceuticals	Mar 31, 2015	BUY	Strong Buy +822.3% avg upside 3 analysts	$5.00 385.44% Upside	-62.5%
CAPR Capricor Therapeutics	Mar 19, 2015	BUY	Strong Buy +68.2% avg upside 12 analysts	$12.00 57.80% Downside	-73.8%
PLUR Pluri	Feb 18, 2015	BUY	Strong Buy +197.0% avg upside 8 analysts	$4.00 97.96% Upside	-59.2%
AGEN Agenus	Jan 09, 2015	BUY	Strong Buy +164.7% avg upside 17 analysts	$6.00 99.99% Upside	-28.5%
ONCSQ OncoSec Medical	Dec 11, 2014	BUY	Strong Buy +4699999900.0% avg upside 9 analysts	$40.00 3999999900.05% Upside	·
PALI Palisade Bio	Oct 13, 2014	HOLD	Strong Buy +1347.1% avg upside 15 analysts	—	-56.1%
KBR KBR	May 05, 2014	BUY	Strong Buy +22.2% avg upside 19 analysts	$17.00 48.28% Downside	-25.3%
SRPT Sarepta Therapeutics	Jul 24, 2013	HOLD	Buy +244.5% avg upside 49 analysts	$39.00 122.53% Upside	-45.2%
GERN Geron	Oct 12, 2010	BUY	Strong Buy +239.8% avg upside 19 analysts	$9.00 614.29% Upside	-63.8%
TSE:CSCI COSCIENS Biopharma	May 10, 2010	BUY	Strong Buy +466.6% avg upside 8 analysts	—	·

🔒 53 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Reni Benjamin — Frequently Asked Questions

How accurate are Reni Benjamin's stock ratings?

Based on the calls 13Foresight could measure, about 29% of Reni's ratings were profitable over a one-year hold, with an average return of -0.5% per rating, or -11.3% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Reni ranked on 13Foresight?

Reni Benjamin is currently ranked #2560 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Reni cover?

Reni most recently has ratings on STRO, WHWK, ALLO, BCYC, IMMP, PRLD, LYEL, IMMX, IOVA, BCAX, HOWL, CMPX and 46 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!